MAP2K7 and plasma cell myeloma: For example, Prof. Ryan M. Young’s team found that oncogenic RAS mutations activate mTORC1 signalling in multiple myeloma and combining mTORC1 and MEK/ERK inhibitors synergize to improve survival in preclinical models (32).